World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guideline update – XIII – Oral immunotherapy for CMA – Systematic review

Waffenschmidt, Siw; Agarwal, Arnav; Dziechciarz, Piotr; Horvath, Andrea; Jebai, Rime; Mihara, Hanako; Roldán, Yetiani; Ansotegui, Ignacio J.; Arasi, Stefania; Assa’ad, Amal; Bahna, Sami L.; Canani, R. Berni; Bognanni, Antonio; Bózzola, Martín; Brožek, Jan; Chu, Derek K.; Dahdah, Lamia; Dupont, Christophe; Ebisawa, Motohiro; Fiocchi, Alessandro; Firmino, Ramon Targino; Galli, Elena; Kamenwa, Rose; Lack, Gideon; Li, Haiqi; Martelli, Alberto M.; Nowak‐Węgrzyn, Anna; Papadopoulos, N.; Pawankar, Ruby; Said, Maria; Sánchez-Borges, Mario; Shamir, Raanan; Spergel, Jonathan M.; Szajewska, Hania; Terracciano, Luigi; Vandenplas, Yvan; Venter, Carina; Warner, Amena; Waserman, Susan; Wong, GaryW.K.

doi:10.1016/j.waojou.2022.100682

Cited by 11 publications

(9 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…anaphylaxis) or eosinophilic oesophagitis, an AAF might be indicated. 13,14 In addition to proven efficacy, these formulas need to be nutritionally complete and support normal growth and development. 15 Whilst soya formula (SF) is not an FSMP, this formula can be used in infants >6 months as long as they are not soya allergic.…”

Section: Bms and Prevention Of Allergic Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Working with companies that manufacture breastmilk substitutes: An EAACI position paper

Arasi,

Caubet,

Ceylan

et al. 2024

Pediatric Allergy Immunology

Self Cite

View full text Add to dashboard Cite

Breastmilk is the optimal source of nutrition for infants and should ideally be provided exclusively for the first 6 months of life, and alongside complementary food until 2 years of life. However, there are circumstances where a breastmilk substitute (BMS) may be required. This includes maternal and/or child conditions or personal preference. Whilst these circumstances should never be used as an opportunity to promote BMS, healthcare professionals (HCPs) need to have the knowledge of suitable alternatives and should always be guided by scientific and health motives when recommending a BMS. The Task Force ‘Milk Formula Industry Sponsorship’ from the European Academy of Allergy and Clinical Immunology (EAACI), provides with this publication recommendations for EAACI interactions with the BMS manufacturers and how this will be supervised.

show abstract

Section: Bms and Prevention Of Allergic Diseasesmentioning

confidence: 99%

“…Moreover, in severe CMA (i.e. anaphylaxis) or eosinophilic oesophagitis, an AAF might be indicated 13,14 . In addition to proven efficacy, these formulas need to be nutritionally complete and support normal growth and development 15 .…”

Section: Introductionmentioning

confidence: 99%

Working with companies that manufacture breastmilk substitutes: An EAACI position paper

Arasi,

Caubet,

Ceylan

et al. 2024

Pediatric Allergy Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several systematic reviews have addressed OIT as a treatment for peanut, egg, and/or milk allergy 12,18–22 . Nurmatov et al's 18 systematic review included 25 RCTs and 6 non‐randomized studies published up to March 2016.…”

Section: Introductionmentioning

confidence: 99%

“…16,17 Several systematic reviews have addressed OIT as a treatment for peanut, egg, and/or milk allergy. 12,[18][19][20][21][22] Nurmatov et al's 18 systematic review included 25 RCTs and 6 non-randomized studies published up to March 2016. A limitation of this systematic review was the pooling of heterogeneous studies and methods.…”

mentioning

confidence: 99%

Efficacy and safety of oral immunotherapy for peanut, cow's milk, and hen's egg allergy: A systematic review of randomized controlled trials

Lodge

Waidyatillake

Peters

et al. 2023

Clinical & Translational All

View full text Add to dashboard Cite

Background Oral immunotherapy (OIT) is a promising treatment for food allergies; however, safety is a concern. We synthesized evidence from the best randomized controlled trials (RCTs) on efficacy/safety of OIT for desensitization (DS) and remission (sustained unresponsiveness (SU)) in IgE mediated allergy to peanut, hen's eggs, and cow's milk. Body We searched Pubmed, EMBASE, and Cochrane databases (Until Oct 22) identifying 16 eligible RCTs published in English measuring food allergy by food challenge at the beginning and at the end of the study. The Cochrane Risk of Bias tool was used to assess study quality. We found 18 eligible studies. There was evidence of efficacy for DS for all allergens: peanut (RR 11.32; 95% CI 5.93, 21.60, I2 49%, 8 studies); hen's egg (RR 4.67; 2.66, 8.21, I2 0%, 5 studies); cow's milk (RR 13.98; 3.51, 55.65, I2 0%, 4 studies) and evidence for SU for peanut (RR 7.74; 2.90, 20.69, I2 0%, 3 studies) and hen's egg (RR 6.91; 1.67, 28.57, I2 0%, 2 studies). Allergic events were increased with intervention, and risk of adrenaline use increased for peanut RR 2.96; 1.63, 5.35, I2 0%, 8 studies; egg RR 1.71; 0.42, 6.92, I2 0%, 6 studies; and milk RR 8.45; 2.02, 35.27, I2 0%, 4 studies. Conclusion We found strong evidence that peanut, hen's egg, and cow's milk OIT can induce DS and some evidence for remission. There was a high risk of allergic reactions. Generalizability to the entire food allergic population is not known.

show abstract

“…These are just some of the questions that spontaneously arise when faced with the new approval of the Omalizumab indication. Others concern the opportunity to select patients based on their severity [17], the cost–benefit ratio of the drug [18], its use in patients with pretreatment IgE exceeding 1850 kUI/l [19], and the need for predictive indices of its effectiveness [20]. Beyond them, what is certain is the FDA approval is an epochal event as also recorded by the mainstream press (https://www.nytimes.com/2024/02/25/health/children-food-allergies-xolair.html, accessed on 15 March 2024).…”

mentioning

confidence: 99%

Omalizumab is the Columbus egg for food allergies

Fiocchi,

Ebisawa

2024

Current Opinion in Allergy &Amp; Clinical Immunology

Self Cite

View full text Add to dashboard Cite

World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guideline update – XIII – Oral immunotherapy for CMA – Systematic review

Cited by 11 publications

References 90 publications

Working with companies that manufacture breastmilk substitutes: An EAACI position paper

Working with companies that manufacture breastmilk substitutes: An EAACI position paper

Efficacy and safety of oral immunotherapy for peanut, cow's milk, and hen's egg allergy: A systematic review of randomized controlled trials

Omalizumab is the Columbus egg for food allergies

Contact Info

Product

Resources

About